Is osteopontin a friend or foe of cell apoptosis in inflammatory gastrointestinal and liver diseases?

International Journal of Molecular Sciences

Volumn 19, Issue 1, 2018, Pages

  Iida, Tomoya ^a   Wagatsuma, Kohei ^a   Hirayama, Daisuke ^a   Nakase, Hiroshi ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Cacinogenesis; Gastrointestinal; Inflammation; Liver; Osteopontin

Indexed keywords

ALPHA4 INTEGRIN; HERMES ANTIGEN; MYELOID DIFFERENTIATION FACTOR 88; OSTEOPONTIN;

ACUTE LIVER FAILURE; APOPTOSIS; B LYMPHOCYTE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL SURVIVAL; COLITIS; CYTOKINE PRODUCTION; DENDRITIC CELL; ESOPHAGEAL ADENOCARCINOMA; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HELICOBACTER INFECTION; HELPER CELL; HEPATITIS; IMMUNE RESPONSE; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; LIVER CELL CARCINOMA; LIVER DISEASE; MACROPHAGE; NATURAL KILLER CELL; NEUTROPHIL; NONALCOHOLIC FATTY LIVER; PANCREAS DISEASE; PRIMARY SCLEROSING CHOLANGITIS; PROTEIN EXPRESSION; REVIEW; STOMACH CANCER; T LYMPHOCYTE; ANIMAL; DISEASE EXACERBATION; DISEASE MODEL; HUMAN; METABOLISM; MOUSE; RAT;

ANIMALS; APOPTOSIS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GASTROINTESTINAL DISEASES; HUMANS; INFLAMMATION; LIVER DISEASES; MICE; OSTEOPONTIN; RATS;

EID: 85039707563     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms19010007     Document Type: Review

References (130)

1. Global Action against Cancer-Updated Version; World Health Organization and International Union against Cancer: Geneva, Switzerland, 2005; p. 12.
2. Galdiero, M.R.; Bonavita, E.; Barajon, I.; Garlanda, C.; Mantovani, A.; Jaillon, S. Tumor associated macrophages and neutrophils in cancer. Immunobiology 2013, 218, 1402-1410.
3. Ruffel, B.; Coussens, L.M. Macrophages and therapeutic resistance in cancer. Cancer Cell 2015, 27, 462-472.
4. Shalapour, S.; Karin, M. Immunity, inflammation, and cancer: An eternal fight between good and evil. J. Clin. Investig. 2015, 125, 3347-3355.
5. Grivennikov, S.I.; Greten, F.R.; Karin, M. Immunity, inflammation, and cancer. Cell 2010, 140, 883-899.
6. Chang, H.Y.; Sneddon, J.B.; Alizadeh, A.A.; Sood, R.; West, R.B.; Montgomery, K.; Chi, J.T.; van de Rijn, M.; Botstein, D.; Brown, P.O. Gene expression signature of fibroblast serum response predicts human cancer progression: Similarities between tumors and wounds. PLoS Biol. 2004, 2, E7.
7. Erez, N.; Truitt, M.; Olson, P.; Arron, S.T.; Hanahan, D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-κB-dependent manner. Cancer Cell 2010, 17, 135-147.
8. Franzen, A.; Heinegard, D. Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem. J. 1985, 232, 715-724.
9. Vaschetto, R.; Nicola, S.; Olivieri, C.; Boggio, E.; Piccolella, F.; Mesturini, R.; Damnotti, F.; Colombo, D.; Navalesi, P.; Della Corte, F.; et al. Serum levels of osteopontin are increased in SIRS and sepsis. Intensive Care Med. 2008, 34, 2176-2184.
10. Castello, L.M.; Raineri, D.; Salmi, L.; Clemente, N.; Vaschetto, R.; Quaglia, M.; Garzaro, M.; Gentilli, S.; Navalesi, P.; Cantaluppi, V.; et al. Osteopontin at the Crossroads of Inflammation and Tumor Progression. Mediat. Inflamm. 2017, 2017, 4049098.
11. Fisher, L.W.; Torchia, D.A.; Fohr, B.; Young, M.F.; Fedarko, N.S. Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem. Biophys. Res. Commun. 2007, 280, 460-465.
12. Kazanecki, C.C.; Uzwiak, D.J.; Denhardt, D.T. Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J. Cell. Biochem. 2007, 102, 912-924.
13. Shevde, L.A.; Samant, R.S. Role of osteopontin in the pathophysiology of cancer. Matrix Biol. 2014, 37, 131-141.
14. Denhardt, D.T.; Noda, M.; O’Regan, A.W.; Pavlin, D.; Berman, J.S. Osteopontin as a means to cope with environmental insults: Regulation of inflammation, tissue remodeling, and cell survival. J. Clin. Investig. 2001, 107, 1055-1061.
15. Shinohara, M.L.; Kim, H.J.; Kim, J.H.; Garcia, V.A.; Cantor, H. Alternative translation of osteopontin generates intracellular and secreted isoforms that mediate distinct biological activities in dendritic cells. Proc. Natl. Acad. Sci. USA 2008, 105, 7235-7239.
16. Wang, K.X.; Denhardt, D.T. Osteopontin: Role in immuneregulation and stress responses. Cytokine Growth Factor Rev. 2008, 19, 333-345.
17. Ramaiah, S.K.; Rittling, S. Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol. Sci. 2008, 103, 4-13.
18. Rittling, S.R.; Chambers, A.F. Role of osteopontin in tumour progression. Br. J. Cancer 2004, 90, 1877-1881.
19. Brown, L.F.; Berse, B.; Van de Water, L.; Papadopoulos-Sergiou, A.; Perruzzi, C.A.; Manseau, E.J.; Dvorak, H.F.; Senger, D.R. Expression and distribution of osteopontin in human tissues: Widespread association with luminal epithelial surfaces. Mol. Biol. Cell 1992, 3, 1169-1180.
20. Ashkar, S.; Weber, G.F.; Panoutsakopoulou, V.; Sanchirico, M.E.; Jansson, M.; Zawaideh, S.; Rittling, S.R.; Denhardt, D.T.; Glimcher, M.J.; Cantor, H. Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity. Science 2000, 287, 860-864.
21. Zhang, H.; Guo, M.; Chen, J.H.; Wang, Z.; Du, X.F.; Liu, P.X.; Li, W.H. Osteopontin knockdown inhibits αv, β3 integrin-induced cell migration and invasion and promotes apoptosis of breast cancer cells by inducing autophagy and inactivating the PI3K/Akt/mTOR pathway. Cell Physiol. Biochem. 2014, 33, 991-1002.
22. Liaw, L.; Skinner, M.P.; Raines, E.W.; Ross, R.; Cheresh, D.A.; Schwartz, S.M.; Giachelli, C.M. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J. Clin. Investig. 1995, 95, 713-724.
23. Yokosaki, Y.; Tanaka, K.; Higashikawa, F.; Yamashita, K.; Eboshida, A. Distinct structural requirements for binding of the integrins αvβ6, αvβ3, αvβ5, α5β1 and α9β1 to osteopontin. Matrix Biol. 2005, 24, 418-427.
24. Green, P.M.; Ludbrook, S.B.; Miller, D.D.; Horgan, C.M.; Barry, S.T. Structural elements of the osteopontin SVVYGLR motif important for the interaction with α(4) integrins. FEBS Lett. 2001, 503, 75-79.
25. Marcondes, M.C.; Poling, M.; Watry, D.D.; Hall, D.; Fox, H.S. In vivo osteopontin-induced macrophage accumulation is dependent on CD44 expression. Cell. Immunol. 2008, 254, 56-62.
26. Lund, S.A.; Wilson, C.L.; Raines, E.W.; Tang, J.; Giachelli, C.M.; Scatena, M. Osteopontin mediates macrophage chemotaxis via α4 and α9 integrins and survival via the α4 integrin. J. Cell. Biochem. 2013, 114, 1194-1202.
27. Das, R.; Philip, S.; Mahabeleshwar, G.H.; Bulbule, A.; Kundu, G.C. Osteopontin: It’s role in regulation of cell motility and nuclear factor κB-mediated urokinase type plasminogen activator expression. IUBMB Life 2005, 57, 441-447.
28. Viatour, P.; Merville, M.P.; Bours, V.; Chariot, A. Phosphorylation of NF-κB and IκB proteins: Implications in cancer and inflammation. Trends Biochem. Sci. 2005, 30, 43-52.
29. Renkl, A.C.; Wussler, J.; Ahrens, T.; Thoma, K.; Kon, S.; Uede, T.; Martin, S.F.; Simon, J.C.; Weiss, J.M. Osteopontin functionally activates dendritic cells and induces their differentiation toward a Th1-polarizing phenotype. Blood 2005, 106, 946-955.
30. Kawamura, K.; Iyonaga, K.; Ichiyasu, H.; Nagano, J.; Suga, M.; Sasaki, Y. Differentiation, maturation, and survival of dendritic cells by osteopontin regulation. Clin. Diagn. Lab. Immunol. 2005, 12, 206-212.
31. Weiss, J.M.; Renkl, A.C.; Maier, C.S.; Kimmig, M.; Liaw, L.; Ahrens, T.; Kon, S.; Maeda, M.; Hotta, H.; Uede, T.; et al. Osteopontin is involved in the initiation of cutaneous contact hypersensitivity by inducing Langerhans and dendritic cell migration to lymph nodes. J. Exp. Med. 2001, 194, 1219-1229.
32. Hirano, Y.; Azi, M.; Yang, W.L.; Wang, Z.; Zhou, M.; Ochani, M.; Khader, A.; Wang, P. Neutralization of osteopontin attenuates neutrophil migration in sepsis-induced acute lung injury. Crit. Care 2015, 19, 53.
33. Koh, A.; da Silva, A.P.; Bansal, A.K.; Bansal, M.; Sun, C.; Lee, H.; Glogauer, M.; Sodek, J.; Zohar, R. Role of osteopontin in neutrophil function. Immunology 2007, 122, 466-475.
34. Singh, R.; Hui, T.; Matsui, A.; Allahem, Z.; Johnston, C.D.; Ruiz-Torruella, M.; Rittling, S.R. Modulation of infection-mediated migration of neutrophils and CXCR2 trafficking by osteopontin. Immunology 2017, 150, 74-86.
35. Leavenworth, J.W.; Verbinnen, B.; Wang, Q.; Shen, E.; Cantor, H. Intracellular osteopontin regulates homeostasis and function of natural killer cells. Proc. Natl. Acad. Sci. USA 2015, 112, 494-499.
36. Zhang, Z.X.; Shek, K.; Wang, S.; Huang, X.; Lau, A.; Yin, Z.; Sun, H.; Liu, W.; Garcia, B.; Rittling, S.; et al. Osteopontin expressed in tubular epithelial cells regulates NK cell-mediated kidney ischemia reperfusion injury. J. Immunol. 2010, 185, 967-973.
37. Cen, C.; Aziz, M.; Yang, W.L.; Nicastro, J.M.; Coppa, G.F.; Wang, P. Osteopontin Blockade Attenuates Renal Injury After Ischemia Reperfusion by Inhibiting NK Cell Infiltration. Shock 2017, 47, 52-60.
38. Fan, X.; He, C.; Jing, W.; Zhou, X.; Chen, R.; Cao, L.; Zhu, M.; Jia, R.; Wang, H.; Guo, Y.; et al. Intracellular osteopontin inhibits toll-like receptor signaling and impedes liver carcinogenesis. Cancer Res. 2015, 75, 86-97.
39. Leavenworth, J.W.; Verbinnen, B.; Yin, J.; Huang, H.; Cantor, H. A p85α-osteopontin axis couples the receptor ICOS to sustained Bcl-6 expression by follicular helper and regulatory T cells. Nat. Immunol. 2015, 16, 96-106.
40. Fan, K.; Dai, J.; Wang, H.; Wei, H.; Cao, Z.; Hou, S.; Qian, W.; Li, B.; Zhao, J.; Xu, H.; et al. Treatment of collagen-induced arthritis with an anti-osteopontin monoclonal antibody through promotion of apoptosis of both murine and human activated T cells. Arthritis Rheum. 2008, 58, 2041-2052.
41. Lampe, M.A.; Patarca, R.; Iregui, M.V.; Cantor, H. Polyclonal B cell activation by the Eta-1 cytokine and the development of systemic autoimmune disease. J. Immunol. 1991, 147, 2902-2906.
42. Iizuka, J.; Katagiri, Y.; Tada, N.; Murakami, M.; Ikeda, T.; Sato, M.; Hirokawa, K.; Okada, S.; Hatano, M.; Tokuhisa, T.; et al. Introduction of an osteopontin gene confers the increase in B1 cell population and the production of anti-DNA autoantibodies. Lab. Investig. 1998, 78, 1523-1533.
43. Kitagori, K.; Yoshifuji, H.; Oku, T.; Sasaki, C.; Miyata, H.; Mori, K.P.; Nakajima, T.; Ohmura, K.; Kawabata, D.; Yukawa, N.; et al. Cleaved Form of Osteopontin in Urine as a Clinical Marker of Lupus Nephritis. PLoS ONE 2016, 11, e0167141.
44. Clemente, N.; Raineri, D.; Cappellano, G.; Boggio, E.; Favero, F.; Soluri, M.F.; Dianzani, C.; Comi, C.; Dianzani, U.; Chiocchetti, A. Osteopontin Bridging Innate and Adaptive Immunity in Autoimmune Diseases. J. Immunol. Res. 2016, 2016, 7675437.
45. Clemente, N.; Comi, C.; Raineri, D.; Cappellano, G.; Vecchio, D.; Orilieri, E.; Gigliotti, C.L.; Boggio, E.; Dianzani, C.; Sorosina, M.; et al. Role of Anti-Osteopontin Antibodies in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. Front. Immunol. 2017, 8, 321.
46. Dianzani, C.; Bellavista, E.; Liepe, J.; Verderio, C.; Martucci, M.; Santoro, A.; Chiocchetti, A.; Gigliotti, C.L.; Boggio, E.; Ferrara, B.; et al. Extracellular proteasome-osteopontin circuit regulates cell migration with implications in multiple sclerosis. Sci. Rep. 2017, 7, 43718.
47. Ma, N.; He, Y.; Xiao, H.; Han, G.; Chen, G.; Wang, Y.; Wang, K.; Hou, C.; Yang, X.; Marrero, B.; et al. BAFF maintains T-cell survival by inducing OPN expression in B cells. Mol. Immunol. 2014, 57, 129-137.
48. Chiche, J.; Rouleau, M.; Gounon, P.; Brahimi-Horn, M.C.; Pouyssegur, J.; Mazure, N.M. Hypoxic enlarged mitochondria protect cancer cells from apoptotic stimuli. J. Cell. Physiol. 2010, 222, 648-657.
49. Lagergren, J.; Bergstrom, R.; Lindgren, A.; Nyren, O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N. Engl. J. Med. 1999, 340, 825-831.
50. Shaheen, N.J.; Richter, J.E. Barrett’s oesophagus. Lancet 2009, 373, 850-861.
51. Kim, S.M.; Park, Y.Y.; Park, E.S.; Cho, J.Y.; Izzo, J.G.; Zhang, D.; Kim, S.B.; Lee, J.H.; Bhutani, M.S.; Swisher, S.G.; et al. Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS ONE 2010, 5, e15074.
52. Lin, J.; Myers, A.L.; Wang, Z.; Nancarrow, D.J.; Ferrer-Torres, D.; Handlogten, A.; Leverenz, K.; Bao, J.; Thomas, D.G.; Wang, T.D.; et al. Osteopontin (OPN/SPP1) isoforms collectively enhance tumor cell invasion and dissemination in esophageal adenocarcinoma. Oncotarget 2015, 6, 22239-22257.
53. Miller, C.T.; Lin, L.; Casper, A.M.; Lim, J.; Thomas, D.G.; Orringer, M.B.; Chang, A.C.; Chambers, A.F.; Giordano, T.J.; Glover, T.W. Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene 2006, 25, 409418.
54. Correa, P.; Haenszel, W.; Cuello, C.; Zavala, D.; Fontham, E.; Zarama, G.; Tannenbaum, S.; Collazos, T.; Ruiz, B. Gastric precancerous process in a high risk population: Cohort follow-up. Cancer Res. 1990, 50, 4737-4740.
55. Kinoshita, H.; Hayakawa, Y.; Koike, K. Metaplasia in the Stomach-Precursor of Gastric Cancer? Int. J. Mol. Sci. 2017, 18, 2063.
56. Rollo, E.E.; Laskin, D.L.; Denhardt, D.T. Osteopontin inhibits nitric oxide production and cytotoxicity by activated RAW264.7 macrophages. J. Leukoc. Biol. 1996, 60, 397-404.
57. Chang, W.L.; Yang, H.B.; Cheng, H.C.; Chuang, C.H.; Lu, P.J.; Sheu, B.S. Increased gastric osteopontin expression by Helicobacter pylori Infection can correlate with more severe gastric inflammation and intestinal metaplasia. Helicobacter 2011, 16, 217-224.
58. Chang, W.L.; Lin, M.Y.; Kuo, H.Y.; Yang, H.B.; Cheng, H.C.; Lu, C.C.; Sheu, B.S. Osteopontin polymorphism increases gastric precancerous intestinal metaplasia susceptibility in Helicobacter pylori infected male. Future Oncol. 2017, 13, 1415-1425.
59. Song, G.; Ming, Y.; Mao, Y.; Bao, S.; Ouyang, G. Osteopontin prevents curcumin-induced apoptosis and promotes survival through Akt activation via αvβ3 integrins in human gastric cancer cells. Exp. Biol. Med. (Maywood) 2008, 233, 1537-1545.
60. Lee, J.L.; Wang, M.J.; Sudhir, P.R.; Chen, G.D.; Chi, C.W.; Chen, J.Y. Osteopontin promotes integrin activation through outsidein and inside-out mechanisms: OPN-CD44V interaction enhances survival in gastrointestinal cancer cells. Cancer Res. 2007, 67, 2089-2097.
61. Gong, M.; Lu, Z.; Fang, G.; Bi, J.; Xue, X. A small interfering RNA targeting osteopontin as gastric cancer therapeutics. Cancer Lett. 2008, 272, 148-159.
62. Lee, S.H.; Park, J.W.; Go, D.M.; Kim, H.K.; Kwon, H.J.; Han, S.U.; Kim, D.Y. Ablation of osteopontin suppresses N-methyl-N-nitrosourea and Helicobacter pylori-induced gastric cancer development in mice. Carcinogenesis 2015, 36, 1550-1560.
63. Tang, R.; Yang, G.; Zhang, S.; Wu, C.; Chen, M. Opposite effects of interferon regulatory factor 1 and osteopontin on the apoptosis of epithelial cells induced by TNF-α in inflammatory bowel disease. Inflamm. Bowel Dis. 2014, 20, 1950-1961.
64. Toyonaga, T.; Nakase, H.; Ueno, S.; Matsuura, M.; Yoshino, T.; Honzawa, Y.; Itou, A.; Namba, K.; Minami, N.; Yamada, S.; et al. Osteopontin Deficiency Accelerates Spontaneous Colitis in Mice with Disrupted Gut Microbiota and Macrophage Phagocytic Activity. PLoS ONE 2015, 10, e0135552.
65. Heilmann, K.; Hoffmann, U.; Witte, E.; Loddenkemper, C.; Sina, C.; Schreiber, S.; Hayford, C.; Holzlöhner, P.; Wolk, K.; Tchatchou, E.; et al. Osteopontin as two-sided mediator of intestinal inflammation. J. Cell. Mol. Med. 2009, 13, 1162-1174.
66. Zhong, J.; Eckhardt, E.R.; Oz, H.S.; Bruemmer, D.; de Villiers, W.J. Osteopontin deficiency protects mice from Dextran sodium sulfate-induced colitis. Inflamm. Bowel Dis. 2006, 12, 790-796.
67. Mannick, E.E.; Cote, R.L.; Schurr, J.R.; Krowicka, H.S.; Sloop, G.D.; Zapata-Velandia, A.; Correa, H.; Ruiz, B.; Horswell, R.; Lentz, J.J. Altered phenotype of dextran sulfate sodium colitis in interferon regulatory factor-1 knock-out mice. J. Gastroenterol. Hepatol. 2005, 20, 371-380.
68. Arai, M.; Yokosuka, O.; Kanda, T.; Fukai, K.; Imazeki, F.; Muramatsu, M.; Seki, N.; Miyazaki, M.; Ochiai, T.; Hirasawa, H.; et al. Serum osteopontin levels in patients with acute liver dysfunction. Scand. J. Gastroenterol. 2006, 41, 102-110.
69. Srungaram, P.; Rule, J.A.; Yuan, H.J.; Reimold, A.; Dahl, B.; Sanders, C.; Lee, W.M.; Acute Liver Failure Study Group. Plasma osteopontin in acute liver failure. Cytokine 2015, 73, 270-276.
70. Yilmaz, Y.; Ozturk, O.; Alahdab, Y.O.; Senates, E.; Colak, Y.; Doganay, H.L.; Coskunpinar, E.; Oltulu, Y.M.; Eren, F.; Atug, O.; et al. Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease. Dig. Liver Dis. 2013, 45, 58-62.
71. Seth, D.; Leo, M.A.; McGuinness, P.H.; Lieber, C.S.; Brennan, Y.; Williams, R.; Wang, X.M.; McCaughan, G.W.; Gorrell, M.D.; Haber, P.S. Gene expression profiling of alcoholic liver disease in the baboon (Papio hamadryas) and human liver. Am. J. Pathol. 2003, 163, 2303-2317.
72. Zhao, L.; Li, T.; Wang, Y.; Pan, Y.; Ning, H.; Hui, X.; Xie, H.; Wang, J.; Han, Y.; Liu, Z.; et al. Elevated plasma osteopontin level is predictive of cirrhosis in patients with hepatitis B infection. Int. J. Clin. Pract. 2008, 62, 1056-1062.
73. Huang, W.; Zhu, G.; Huang, M.; Lou, G.; Liu, Y.; Wang, S. Plasma osteopontin concentration correlates with the severity of hepatic fibrosis and inflammation in HCV-infected subjects. Clin. Chim. Acta 2010, 411, 675-678.
74. Matsue, Y.; Tsutsumi, M.; Hayashi, N.; Saito, T.; Tsuchishima, M.; Toshikuni, N.; Arisawa, T.; George, J. Serum osteopontin predicts degree of hepatic fibrosis and serves as a biomarker in patients with hepatitis C virus infection. PLoS ONE 2015, 10, e0118744.
75. Harada, K.; Ozaki, S.; Sudo, Y.; Tsuneyama, K.; Ohta, H.; Nakanuma, Y. Osteopontin is involved in the formation of epithelioid granuloma and bile duct injury in primary biliary cirrhosis. Pathol. Int. 2003, 53, 8-17.
76. Seth, D.; Duly, A.; Kuo, P.C.; McCaughan, G.W.; Haber, P.S. Osteopontin is an important mediator of alcoholic liver disease via hepatic stellate cell activation. World J. Gastroenterol. 2014, 20, 13088-13104.
77. Geisler, F.; Strazzabosco, M. Emerging roles of Notch signaling in liver disease. Hepatology 2015, 61, 382-392.
78. Williams, M.J.; Clouston, A.D.; Forbes, S.J. Links between hepatic fibrosis, ductular reaction, and progenitor cell expansion. Gastroenterology 2014, 146, 349-356.
79. Wang, X.; Lopategi, A.; Ge, X.; Lu, Y.; Kitamura, N.; Urtasun, R.; Leung, T.M.; Fiel, M.I.; Nieto, N. Osteopontin induces ductular reaction contributing to liver fibrosis. Gut 2014, 63, 1805-1818.
80. Banerjee, A.; Burghardt, R.C.; Johnson, G.A.; White, F.J.; Ramaiah, S.K. The temporal expression of osteopontin (SPP-1) in the rodent model of alcoholic steatohepatitis: A potential biomarker. Toxicol. Pathol. 2006, 34, 373-384.
81. Lazaro, R.; Wu, R.; Lee, S.; Zhu, N.L.; Chen, C.L.; French, S.W.; Xu, J.; Machida, K.; Tsukamoto, H. Osteopontin deficiency does not prevent but promotes alcoholic neutrophilic hepatitis in mice. Hepatology 2015, 61, 129-140.
82. Ge, X.; Leung, T.M.; Arriazu, E.; Lu, Y.; Urtasun, R.; Christensen, B.; Fiel, M.I.; Mochida, S.; Sørensen, E.S.; Nieto, N. Osteopontin binding to lipopolysaccharide lowers tumor necrosis factor-α and prevents early alcohol-induced liver injury in mice. Hepatology 2014, 59, 1600-1616.
83. Wang, G.; Chen, S.; Zhao, C.; Li, X.; Zhao, W.; Yang, J.; Chang, C.; Xu, C. Comparative analysis of gene expression profiles of OPN signaling pathway in four kinds of liver diseases. J. Genet. 2016, 95, 741-750.
84. Wang, G.; Zhao, C.; Chen, S.; Li, X.; Zhang, L.; Chang, C.; Xu, C. A preliminary in vivo study of the effects of OPN on rat liver regeneration induced by partial hepatectomy. Mol. Biol. Rep. 2016, 43, 1371-1382.
85. Nagoshi, S. Osteopontin: Versatile modulator of liver disease. Hepatol. Res. 2014, 44, 22-30.
86. Pan, H.W.; Ou, Y.H.; Peng, S.Y.; Liu, S.H.; Lai, P.L.; Lee, P.H.; Sheu, J.C.; Chen, C.L.; Hsu, H.C. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 2003, 98, 119-127.
87. Yu, M.C.; Lee, Y.S.; Lin, S.E.; Wu, H.Y.; Chen, T.C.; Lee, W.C.; Chen, M.F.; Tsai, C.N. Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin. Ann. Surg. Oncol. 2012, 19, S455-S463.
88. Zhao, J.; Dong, L.; Lu, B.; Wu, G.; Xu, D.; Chen, J.; Li, K.; Tong, X.; Dai, J.; Yao, S.; et al. Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis. Gastroenterology 2008, 135, 956-968.
89. Lee, S.H.; Park, J.W.; Woo, S.H.; Go, D.M.; Kwon, H.J.; Jang, J.J.; Kim, D.Y. Suppression of osteopontin inhibits chemically induced hepatic carcinogenesis by induction of apoptosis in mice. Oncotarget 2016, 7, 87219-87231.
90. Lee, K.T.; Liu, T.S. Altered mucin gene expression in stone-containing intrahepatic bile ducts and cholangiocarcinomas. Dig. Dis. Sci. 2001, 46, 2166-2172.
91. Nakanuma, Y.; Yamaguchi, K.; Ohta, G.; Terada, T. Pathologic features of hepatolithiasis in Japan. Hum. Pathol. 1998, 19, 1181-1186.
92. Nakanuma, Y.; Sasaki, M.; Terada, T.; Harada, K. Intrahepatic peribiliary glands of humans. II. Pathological spectrum. J. Gastroenterol. Hepatol. 1994, 9, 80-86.
93. Yamamoto, K. Intrahepatic periductal glands and their significance in primary intrahepatic lithiasis. Jpn. J. Surg. 1982, 12, 163-170.
94. Kim, B.S.; Joo, S.H.; Lim, S.J.; Joo, K.R. Osteopontin Expression in Patients with Hepatolith. Indian J. Surg. 2015, 77, 551-556.
95. Nakai, A.; Imano, M.; Takeyama, Y.; Shiozaki, H.; Ohyanagi, H. An immunohistochemical study of osteopontin in hepatolithiasis. J. Hepatobiliary Pancreat. Surg. 2008, 15, 615-621.
96. Terashi, T.; Aishima, S.; Taguchi, K.; Asayama, Y.; Sugimachi, K.; Matsuura, S.; Shimada, M.; Maehara, S.; Maehara, Y.; Tsuneyoshi, M. Decreased expression of osteopontin is related to tumor aggressiveness and clinical outcome of intrahepatic cholangiocarcinoma. Liver Int. 2004, 24, 38-45.
97. Sulpice, L.; Rayar, M.; Desille, M.; Turlin, B.; Fautrel, A.; Boucher, E.; Llamas-Gutierrez, F.; Meunier, B.; Boudjema, K.; Clément, B.; et al. Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma. Hepatology 2013, 58, 1992-2000.
98. Zhang, J.; Jiao, J.; Cermelli, S.; Muir, K.; Jung, K.H.; Zou, R.; Rashid, A.; Gagea, M.; Zabludoff, S.; Kalluri, R.; et al. miR-21 Inhibition Reduces Liver Fibrosis and Prevents Tumor Development by Inducing Apoptosis of CD24+ Progenitor Cells. Cancer Res. 2015, 75, 1859-1867.
99. Razumilava, N.; Gores, G.J. Cholangiocarcinoma. Lancet 2014, 383, 2168-2179.
100. Rizvi, S.; Gores, G.J. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 2013, 145, 1215-1229.
101. Tanaka, M.; Tanaka, H.; Tsukuma, H.; Ioka, A.; Oshima, A.; Nakahara, T. Risk factors for intrahepatic cholangiocarcinoma: A possible role of hepatitis B virus. J. Viral Hepat. 2010, 17, 742-748.
102. Fickert, P.; Thueringer, A.; Moustafa, T.; Silbert, D.; Gumhold, J.; Tsybrovskyy, O.; Lebofsky, M.; Jaeschke, H.; Denk, H.; Trauner, M. The role of osteopontin and tumor necrosis factor α receptor-1 in xenobiotic-induced cholangitis and biliary fibrosis in mice. Lab. Investig. 2010, 90, 844-852.
103. Pereira, T.A.; Syn, W.K.; Machado, M.V.; Vidigal, P.V.; Resende, V.; Voieta, I.; Xie, G.; Otoni, A.; Souza, M.M.; Santos, E.T.; et al. Schistosome-induced cholangiocyte proliferation and osteopontin secretion correlate with fibrosis and portal hypertension in human and murine schistosomiasis mansoni. Clin. Sci. 2015, 129, 875-883.
104. Tannapfel, A.; Sommerer, F.; Benicke, M.; Katalinic, A.; Uhlmann, D.; Witzigmann, H.; Hauss, J.; Wittekind, C. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003, 52, 706-712.
105. Zheng, T.; Hong, X.; Wang, J.; Pie, T.; Liang, Y.; Yin, D.; Song, R.; Song, X.; Lu, Z.; Qi, S.; et al. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma. Hepatology 2014, 59, 935-946.
106. Isomoto, H.; Mott, J.L.; Kobayashi, S.; Warneburg, N.W.; Bronk, S.F.; Haan, S.; Gores, G.J. Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology 2007, 132, 384-396.
107. Lu, D.; Han, C.; Wu, T. 15-hydroxyprostaglandin dehydrogenase-derived 15-keto-prostaglandin E2 inhibits cholangiocarcinoma cell growth through interaction with peroxisome proliferator-activated receptor-γ, SMAD2/3, and TAP63 proteins. J. Biol. Chem. 2013, 288, 19484-19502.
108. Techasen, A.; Namwat, N.; Loilome, W.; Bungkanjana, P.; Khuntikeo, N.; Puapairoj, A.; Jearanaikoon, P.; Saya, H.; Yongvanit, P. Tumor necrosis factor-α (TNF-α) stimulates the epithelial-mesenchymal transition regulator Snail in cholangiocarcinoma. Med. Oncol. 2012, 29, 3083-3091.
109. Huang, Q.X.; Cui, J.Y.; Ma, H.; Jia, X.M.; Huang, F.L.; Jiang, L.X. Screening of potential biomarkers for cholangiocarcinoma by integrated analysis of microarray data sets. Cancer Gene Ther. 2016, 23, 48-53.
110. Laohaviroj, M.; Chamgramol, Y.; Pairojkul, C.; Mulvenna, J.; Sripa, B. Clinicopathological Significance of Osteopontin in Cholangiocarcinoma Cases. Asian Pac. J. Cancer Prev. 2016, 17, 201-205.
111. Loosen, S.H.; Roderburg, C.; Kauertz, K.L.; Pombeiro, I.; Leyh, C.; Benz, F.; Vucur, M.; Longerich, T.; Koch, A.; Braunschweig, T.; et al. Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma. J. Hepatol. 2017, 67, 749-757.
112. Lustri, A.M.; Di Matteo, S.; Fraveto, A.; Costantini, D.; Cantafora, A.; Napoletano, C.; Bragazzi, M.C.; Giuliante, F.; De Rose, A.M.; Berloco, P.B.; et al. TGF-β signaling is an effective target to impair survival and induce apoptosis of human cholangiocarcinoma cells: A study on human primary cell cultures. PLoS ONE 2017, 12, e0183932.
113. Isomoto, H.; Kobayashi, S.; Werneburg, N.W.; Bronk, S.F.; Guicciardi, M.E.; Frank, D.A.; Gores, G.J. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology 2005, 42, 1329-1338.
114. Takemoto, M.; Yokote, K.; Yamazaki, M.; Ridall, A.L.; Butler, W.T.; Matsumoto, T.; Tamura, K.; Saito, Y.; Mori, S. Enhanced expression of osteopontin by high glucose in cultured rat aortic smooth muscle cells. Biochem. Biophys. Res. Commun. 1999, 258, 722-726.
115. Hsieh, M.S.; Zhong, W.B.; Yu, S.C.; Lin, J.Y.; Chi, W.M.; Lee, H.M. Dipyridamole suppresses high glucose-induced osteopontin secretion and mRNA expression in rat aortic smooth muscle cells. Circ. J. 2010, 74, 1242-1250.
116. Katakam, A.K.; Chipitsyna, G.; Gong, Q.; Vancha, A.R.; Gabβ, J.; Arafat, H.A. Streptozotocin (STZ) mediates acute upregulation of serum and pancreatic osteopontin (OPN): A novel islet-protective effect of OPN through inhibition of STZ-induced nitric oxide production. J. Endocrinol. 2005, 187, 237-247.
117. Arafat, H.A.; Katakam, A.K.; Chipitsyna, G.; Gong, Q.; Vancha, A.R.; Gabβ, J.; Dafoe, D.C. Osteopontin protects the islets and β-cells from interleukin-1 β-mediated cytotoxicity through negative feedback regulation of nitric oxide. Endocrinology 2007, 148, 575-584.
118. Lyssenko, V.; Eliasson, L.; Kotova, O.; Pilgaard, K.; Wierup, N.; Salehi, A.; Wendt, A.; Jonsson, A.; De Marinis, Y.Z.; Berglund, L.M.; et al. Pleiotropic effects of GIP on islet function involve osteopontin. Diabetes 2011, 60, 2424-2433.
119. Nakamura, M.; Oka, M.; Iizuka, N.; Kawauchi, S.; Gondo, T.; Ueno, T.; Tangoku, A. Osteopontin expression in chronic pancreatitis. Pancreas 2002, 25, 182-187.
120. Takada, H.; Nakazawa, T.; Ohara, H.; Ando, T.; Hayashi, K.; Naito, I.; Okumura, F.; Tanaka, H.; Yamada, T.; Takahashi, S.; et al. Role of osteopontin in calcification in autoimmune pancreatitis. Dig. Dis. Sci. 2009, 54, 793-801.
121. Rychlíková, J.; Vecka, M.; Jáchymová, M.; Macášek, J.; Hrabák, P.; Zeman, M.; Vávrová, L.; Řoupal, J.; Krechler, T.; Ák, A. Osteopontin as a discriminating marker for pancreatic cancer and chronic pancreatitis. Cancer Biomark. 2016, 17, 55-65.
122. Kolb, A.; Kleeff, J.; Guweidhi, A.; Esposito, I.; Giese, N.A.; Adwan, H.; Giese, T.; Büchler, M.W.; Berger, M.R. Friess, H. Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions. Cancer Biol. Ther. 2005, 4, 740-746.
123. Li, J.J.; Li, H.Y.; Gu, F. Diagnostic significance of serum osteopontin level for pancreatic cancer: A meta-analysis. Genet. Test. Mol. Biomark. 2014, 18, 580-586.
124. Ito, M.; Makino, N.; Matsuda, A.; Ikeda, Y.; Kakizaki, Y.; Saito, Y.; Ueno, Y.; Kawata, S. High Glucose Accelerates Cell Proliferation and Increases the Secretion and mRNA Expression of Osteopontin in Human Pancreatic Duct Epithelial Cells. Int. J. Mol. Sci. 2017, 18, 807.
125. Collins, A.L.; Rock, J.; Malhotra, L.; Frankel, W.L.; Bloomston, M. Osteopontin expression is associated with improved survival in patients with pancreatic adenocarcinoma. Ann. Surg. Oncol. 2012, 19, 2673-2678.
126. Weber, C.E.; Erşahin, Ç.H.; Kuo, P.C.; Mi, Z. Pancreatic Cancer and Osteopontin: The Relationship Remains Unclear. Pancreas 2016, 45, e35-e36.
127. Ferrara, J.L.; Levine, J.E.; Reddy, P.; Holler, E. Graft-versus-host disease. Lancet 2009, 373, 1550-1561.
128. Markey, K.A.; MacDonald, K.P.; Hill, G.R. The biology of graft-versus-host disease: Experimental systems instructing clinical practice. Blood 2014, 124, 354-362.
129. Zhao, F.; Zhang, Y.; Wang, H.; Jin, M.; He, S.; Shi, Y.; Guo, Y.; Zhang, Y. Blockade of osteopontin reduces alloreactive CD8+T cell-mediated graft-versus-host disease. Blood 2011, 117, 1723-1733.
130. Kawakami, K.; Minami, N.; Matsuura, M.; Iida, T.; Toyonaga, T.; Nagaishi, K.; Arimura, Y.; Fujimiya, M.; Uede, T.; Nakase, H. Osteopontin attenuates acute gastrointestinal graft-versus-host disease by preventing apoptosis of intestinal epithelial cells. Biochem. Biophys. Res. Commun. 2017, 485, 468475.